NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial ...Middle East

PR Newswire - News
NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial
A statistically significant, 37.4% difference (P=0.03), slowing of disease progression in ALSFRS-R, in patients treated with PrimeC compared to placebo, in the pre-specified Per Protocol (PP) population analysis Neurofilament biomarker results from Biogen collaboration expected in January...

Hence then, the article about neurosense reports new data statistically significant clinical efficacy in phase 2b als trial was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial )

Apple Storegoogle play

Last updated :

Also on site :



Latest News